BioTuesdays

Category - Markets

novadaq

Wedbush ups Novadaq price target to $17

Wedbush Securities has raised its price target for “outperform-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to $17 from $15. The stock finished at $11.16 on Wednesday. “Novadaq is the leader in the rapidly growing...

Sophiris Bio Logo

Euro Pacific upgrades Sophiris Bio to buy

Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in...

Strongbridge Biopharma Logo

Stifel starts Strongbridge Biopharma at buy

Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused...

Cogentix Medical

Roth upgrades Cogentix Medical to buy

Roth Capital Partners has upgraded Cogentix Medical (NASDAQ:CGNT) to “buy” from “neutral” and raised its target price to $3 from $1.85. The stock closed at $1.52 on Wednesday. “Given our confidence for Cogentix to...

TearLab

TearLab Q3 revenue climbs 27%

Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter. “We delivered a strong growth quarter...

Aclaris Therapeutics

William Blair starts Aclaris Therapeutics at outperform

William Blair has launched coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $30 price target. The stock closed at $14.38 on Friday. Aclaris’ lead program, A-101, is a topical solution being...

CASI Pharmaceuticals

HCW assumes coverage of CASI Pharma at buy

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of CASI Pharmaceuticals (NASDAQ:CASI) with a “buy” rating and $3 price target. The stock closed at $1.21 on Wednesday. CASI is a clinical-stage company...

Rock Creek Pharmaceuticals Logo

Maxim starts Rock Creek Pharma at buy

Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday. Rock Creek’s lead product, anatabine citrate...

Viking Therapeutics Logo

Feltl starts Viking Therapeutics at strong buy

Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday. “We anticipate the company executing on multiple...

Prima BioMed

HCW starts Prima BioMed at buy

H.C. Wainwright has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and $3 price target. The stock closed at $1.22 on Tuesday. Australia-based Prima is developing novel checkpoint modulators (CPMs)...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.